Literature DB >> 20213390

Osteosarcoma lung metastases detection and principles of multimodal therapy.

Dorothe Carrle1, Stefan Bielack.   

Abstract

The management of pulmonary metastases poses a challenge to the multidisciplinary team involved in the treatment of osteosarcoma. A postal survey on the management of pulmonary metastases in osteosarcoma involving 17 representatives from international study groups and selected institutions was performed in which a response rate of 94% was achieved. The results showed uniform approaches in areas like the imaging methods used for initial staging and the use of manual exploration with thoracotomy. However, it demonstrated diverse practices regarding exploration of the unaffected site in unilateral pulmonary disease, and the approach to lesions disappearing under chemotherapy. Furthermore, agreement on the size of a lesion considered to distinguish between benign and of metastatic origin, varied. Based on the survey and a review of the current literature, detection methods and principles of multimodal therapy will be discussed. Prognostic factors in synchronous and metachronous pulmonary metastases and their implications for a multimodal therapy is also presented.

Entities:  

Mesh:

Year:  2009        PMID: 20213390     DOI: 10.1007/978-1-4419-0284-9_8

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  23 in total

1.  High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.

Authors:  Wu Yang; He Maolin; Zhao Jinmin; Wang Zhe
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-08       Impact factor: 4.553

2.  Vitronectin significantly influences prognosis in osteosarcoma.

Authors:  Kai Shi; Rui-Long Lan; Xuan Tao; Chao-Yang Wu; Hai-Feng Hong; Jian-Hua Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 3.  Advances in therapy for pediatric sarcomas.

Authors:  Aaron Weiss; Jonathan Gill; John Goldberg; Joanne Lagmay; Holly Spraker-Perlman; Rajkumar Venkatramani; Damon Reed
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

4.  Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.

Authors:  Danielle M Lussier; John L Johnson; Pooja Hingorani; Joseph N Blattman
Journal:  J Immunother Cancer       Date:  2015-05-19       Impact factor: 13.751

5.  The expression and clinical significance of HDGF in osteosarcoma.

Authors:  Zhiguo Chen; Shenghai Qiu; Xiaofei Lu
Journal:  Onco Targets Ther       Date:  2015-09-09       Impact factor: 4.147

6.  Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.

Authors:  Kjetil Berner; Kirsten Sundby Hall; Odd R Monge; Harald Weedon-Fekjær; Olga Zaikova; Øyvind S Bruland
Journal:  Sarcoma       Date:  2015-02-17

7.  Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway.

Authors:  Meng-Ke Fan; Guo-Chuan Zhang; Wei Chen; Li-Li Qi; Ming-Fang Xie; Yue-Yao Zhang; Ling Wang; Qi Zhang
Journal:  Front Oncol       Date:  2021-07-16       Impact factor: 6.244

8.  B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.

Authors:  Ling Wang; Qi Zhang; Wei Chen; Baoen Shan; Yang Ding; Guochuan Zhang; Nana Cao; Lei Liu; Yingze Zhang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 9.  UK guidelines for the management of bone sarcomas.

Authors:  Craig Gerrand; Nick Athanasou; Bernadette Brennan; Robert Grimer; Ian Judson; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan
Journal:  Clin Sarcoma Res       Date:  2016-05-04

10.  Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.

Authors:  Pratistha Koirala; Michael E Roth; Jonathan Gill; Sajida Piperdi; Jordan M Chinai; David S Geller; Bang H Hoang; Amy Park; Michael A Fremed; Xingxing Zang; Richard Gorlick
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.